Highest-materiality recent filing
Medifast Chief Legal Officer resigns; receives one-month severance of $35,648
Jason L. Groves resigned as Chief Legal Officer & Corporate Secretary effective May 29, 2026; departure not due to any disagreement with the company.
Medifast appoints Nicholas Johnson as CEO; Dan Chard becomes non-executive Chairman
Nicholas Johnson, 46, becomes CEO effective June 1, 2026; Dan Chard transitions to non-executive Chairman.
Medifast Q1 revenue $76M, down 34% YoY; net loss $2.1M; guides Q2 revenue $60-80M
Revenue fell 34.3% to $76.0M; net loss widened to $2.1M ($0.19 EPS) from $0.8M loss.
Medifast (MED) entered a Cooperation Agreement with Steamboat Capital Partners (beneficial owner >5%) on March 19, 2026.
Medifast Q4 revenue falls 37% to $75.1M; net loss $18.1M, guides FY26 rev $270-300M
Revenue $75.1M, down 36.9% YoY; active earning coaches down 40.6% to 16,100.
Anthony Tyree (CBOO) departs Dec 31, 2025; receives $706,984 severance (salary + target bonus).
Medifast Q3 revenue down 36% to $89.4M; net loss $2.3M; coaches drop 35%
Revenue $89.4M vs $140.2M YoY; net loss $0.21 per diluted share vs $0.10 income.
Medifast Q2 revenue falls 37.4% to $105.6M; active coaches down 33%; Q3 guidance weak
Revenue $105.6M, down 37.4% YoY; active OPTA VIA coaches 22,800 (-32.7% YoY); diluted EPS $0.22 (includes $2.0M net LifeMD gain).
Medifast stockholders approve 550k share increase to 2012 incentive plan and re-elect directors
Stockholders approved Amended 2012 Plan adding 550,000 shares to the pool, totaling ~1,175,000 shares available.
Medifast Q1 2025: revenue down 34% to $115.7M, net loss $0.8M; Q2 guidance weak
Revenue fell 33.8% to $115.7M; active earning coaches down 32.8% to 25,400.
Medifast Q4 revenue down 38% to $119M; EPS $0.07; guides Q1 loss
Q4 revenue $119M (-37.7% YoY); active earning coaches 27,100 (-34.1% YoY).
Medifast Q3 2024 revenue down 40.6% to $140.2M; EPS $0.10; guides Q4 revenue $100-120M
Revenue $140.2M, down 40.6% YoY; net income $1.1M ($0.10 diluted EPS); adjusted EPS $0.35.
Medifast Q2 revenue falls 43% to $168.6M; net loss $0.75/share, guides Q3 loss
Revenue $168.6M, down 43.1% YoY; active earning Coaches 33,900 (-36.2%); avg revenue per Coach $4,972 (-10.9%).
Medifast shareholders approve 515K share increase in incentive plan, re-elect board
Stockholders approved amendment to 2012 Share Incentive Plan, increasing share reserve by 515,000 and updating provisions.
Medifast posts 50% revenue decline to $174.7M in Q1; EPS $0.76 vs $3.67 YoY
Revenue of $174.7M, down 49.9% YoY; net income $8.3M ($0.76 diluted EPS) vs $40.0M ($3.67) in Q1 2023.
Medifast Q4 revenue falls 43% to $191M; guides Q1 2024 revenue $155-175M
Q4 net income $6.0M ($0.55 diluted EPS); adjusted net income $11.9M ($1.09 adjusted EPS).
Medifast commits $20M to LifeMD ($10M platform contributions, $10M stock purchase) for collaboration.
Medifast Q3 revenue down 39.6% YoY to $235.9M; EPS $2.12 vs $3.27
Revenue $235.9M (-39.6% YoY); net income $23.1M (-36.2% YoY); diluted EPS $2.12 vs $3.27.
Medifast inadvertently discloses internal target of flat revenue for FY2024; cautions not guidance
Internal target set in early 2023 anticipated flat revenue growth for FY2024.
Medifast declares $1.65 quarterly dividend payable Nov 7, 2023
Quarterly cash dividend of $1.65 per share declared by board.
Medifast Q2 revenue falls 34.7% to $296.2M; diluted EPS $2.77 vs $3.42
Revenue $296.2M (-34.7%); net income $30.3M, EPS $2.77 vs $39.1M, $3.42 prior.
Medifast declares $1.65 quarterly dividend payable Aug 8, 2023
Quarterly cash dividend of $1.65 per share declared; payable Aug 8, 2023 to holders of record June 27, 2023.
Medifast to exit Hong Kong and Singapore, targets 15% growth and 15% margin by 2025
Exits Hong Kong and Singapore operations effective July 1, 2023 due to post-pandemic economic changes.
Medifast Q1 revenue down 16.4% to $349M; guides Q2 revenue $250-270M, EPS $1.32-1.44
Revenue $349M (-16.4% YoY); net income $40M ($3.67 diluted EPS) vs $41.8M ($3.59) prior year.
Medifast EVP Supply Chain Lauren Walker to retire effective May 4, 2023
Lauren Walker, Executive Vice President of Supply Chain, announced her retirement on March 13, 2023.
Medifast declares $1.65 quarterly dividend payable May 9, 2023
Quarterly cash dividend of $1.65 per share declared by Board of Directors.
Medifast Q4 revenue down 10.7% to $337.2M; guides Q1 revenue $300-320M
Q4 GAAP EPS $2.41, adjusted EPS $3.70; net income $26.5M vs $34.0M YoY.
Medifast declares $1.64 quarterly dividend payable Feb 7, 2023
Quarterly cash dividend of $1.64 per share declared by Medifast's Board of Directors.
Medifast Q3 revenue down 5.6%; cuts FY2022 revenue and EPS guidance on macro headwinds
Revenue $390.4M (-5.6% YoY); net income $36.2M ($3.27 diluted EPS). Non-GAAP adjusted EPS $3.32.
Medifast declares $1.64 quarterly dividend payable Nov 8, 2022
Dividend of $1.64 per share declared by Board of Directors.
Revenue $453.3M (+15% YoY); net income $39.1M (-16.7%); adjusted EPS $3.87 (-2.5%).
Medifast declares $1.64 quarterly dividend, reelects directors, and amends executive severance plan
Stockholders elected seven directors to Medifast's board, each receiving over 8.8 million votes for.
Medifast ups revolving credit line to $225M, adds $100M accordion, switches to SOFR
First Amendment to Credit Agreement increased revolving commitments from $125M to $225M.
Medifast launches $100M accelerated share repurchase program
Entered ASR with JPMorgan to repurchase $100M of common stock.
Medifast Q1 revenue up 22.6% to $417.6M; raises FY22 guidance
Net income $41.8M ($3.59 diluted EPS) vs $41.1M ($3.46) YoY.
Medifast declares $1.64 quarterly dividend payable May 9, 2022
Quarterly cash dividend of $1.64 per share declared by Board of Directors.
Medifast Q4 revenue $377.8M (+42.6%); FY 2021 revenue $1.526B (+63.2%)
Q4 diluted EPS $2.91 vs $2.36 YoY; net income $34.0M (+21.5%).
Medifast declares $1.42 quarterly dividend payable Feb 8, 2022
Board declared a quarterly cash dividend of $1.42 per share.
Medifast Q3 revenue jumps 52% to $413M; EPS $3.56; coaches up 45%
Revenue increased 52.3% to $413.4M; net income $42.0M, diluted EPS $3.56 (up 22.3%).
Medifast appoints Jonathan B. MacKenzie as Chief Accounting Officer effective Sept 13, 2021
MacKenzie succeeds James P. Maloney, who remains CFO; Maloney ceases as Interim CAO.
Medifast declares $1.42 quarterly dividend, payable Nov 8 to holders of record Sep 21
Quarterly cash dividend of $1.42 per share declared by Board of Directors.
Medifast enters separation agreement with departing CAO Stephen Johnson; $106,962 severance
CAO Stephen Johnson departed Aug 5, 2021; no disagreement with company or accounting practices.
Medifast CAO Stephen K. Johnson departs; CFO Maloney assumes interim role
Stephen K. Johnson resigned as Chief Accounting Officer effective August 5, 2021.
Medifast Q2 2021 revenue $394.2M (+79% YoY), EPS $3.96; FY guidance $1.425-1.525B
Revenue $394.2M, up 79.2% YoY; net income $47M (+114.1%); diluted EPS $3.96 (+112.9%).
Effective as of May 29, 2026, Jason L. Groves, Esq., the Chief Legal Officer & Corporate Secretary of Medifast, Inc. (the “Company”), tendered his resignation from the Company.
On May 20, 2026, the Board appointed Nicholas Johnson, age 46, to serve as Chief Executive Officer of the Company, effective June 1, 2026.
On March 13, 2023, Lauren Walker, Executive Vice President, Supply Chain of Medifast, Inc. (the "Company") informed the Company of her intention to retire, effective May 4, 2023.
Effective as of September 13, 2021, the Board of Directors of Medifast, Inc. (the “Company”) appointed Jonathan B. MacKenzie to serve as Chief Accounting Officer of the Company.
Mr. MacKenzie succeeds James P. Maloney, who will cease to serve as the Company’s Interim Chief Accounting Officer upon the effectiveness of Mr. MacKenzie’s employment.
reported the departure of Stephen K. Johnson, the Company’s Chief Accounting Officer, effective August 5, 2021.
James P. Maloney, the Company’s Chief Financial Officer, will serve as interim principal accounting officer as of the effective date of Mr. Johnson’s resignation.
On August 5, 2021, Medifast, Inc. (the “Company”) and Stephen K. Johnson, the Company’s Chief Accounting Officer, agreed that Mr. Johnson will depart from his position as Chief Accounting Officer and all other positions that he holds as an officer or employee of the Company, effective August 5, 2021.
Max materiality 0.90 · Median 0.75 · Most common event earnings